These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 5549140)

  • 1. [Studies on the behavior of fat metabolism during treatment of fatty liver with Nucleoton].
    Kark B
    Med Welt; 1971 Mar; 10():400-1. PubMed ID: 5549140
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of fatty liver with essential phospholipids].
    Arendt R; Nowotny P; Teichmann W
    Z Gesamte Inn Med; 1970 Jul; 25(13):587-9. PubMed ID: 5523267
    [No Abstract]   [Full Text] [Related]  

  • 3. [Behavior of serum transaminases following physical stress in patients with liver diseases].
    Zwirner K
    Acta Hepatosplenol; 1970; 17(2):97-103. PubMed ID: 5524295
    [No Abstract]   [Full Text] [Related]  

  • 4. Protective effects of the Alisma orientalis extract on the experimental nonalcoholic fatty liver disease.
    Hong X; Tang H; Wu L; Li L
    J Pharm Pharmacol; 2006 Oct; 58(10):1391-8. PubMed ID: 17034663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hepatotoxicity of caffeine and theophylline].
    Strubelt O; Wegener F; Siegers CP
    Arzneimittelforschung; 1970 Apr; 20(4):473-6. PubMed ID: 5467807
    [No Abstract]   [Full Text] [Related]  

  • 6. Elevated AST or ALT to nonalcoholic fatty liver disease: accurate predictor of disease prevalence?
    Yu AS; Keeffe EB
    Am J Gastroenterol; 2003 May; 98(5):955-6. PubMed ID: 12809814
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effect of chlorfibrinic acid on the triglyceride and glycogen contents of human liver as well as on blood-level forming metabolites].
    Hanefeld M; Jaross W; Trübsbach A; Leonhardt W
    Z Gesamte Inn Med; 1972 Aug; 27(15):655-8. PubMed ID: 4629764
    [No Abstract]   [Full Text] [Related]  

  • 8. [Importance of hypertransaminasemia in blood donors. Study performed in patients of the Saint Thomas Hospital].
    Narváez E; de Lozano D; Perez Ferrari R
    Rev Med Panama; 1983 Jan; 8(1):45-9. PubMed ID: 6828781
    [No Abstract]   [Full Text] [Related]  

  • 9. [Experimental study on treating hyperlipidemic fatty liver with Taizhi'an capsule].
    Sun M; Shan JZ; Zhang GP; Ying HZ
    Zhongguo Zhong Yao Za Zhi; 2007 Apr; 32(7):616-9. PubMed ID: 17583205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatty liver and transaminase changes with adjuvant tamoxifen therapy.
    Liu CL; Huang JK; Cheng SP; Chang YC; Lee JJ; Liu TP
    Anticancer Drugs; 2006 Jul; 17(6):709-13. PubMed ID: 16917217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Non-alcoholic fatty liver].
    Zwimpfer J
    Praxis (Bern 1994); 2000 Oct; 89(43):1757-8. PubMed ID: 11103621
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
    Bugianesi E; Gentilcore E; Manini R; Natale S; Vanni E; Villanova N; David E; Rizzetto M; Marchesini G
    Am J Gastroenterol; 2005 May; 100(5):1082-90. PubMed ID: 15842582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cytoenzymatic regulations of the liver by free nucleotides. Human bioptic study of subjects with cirrhosis, steatosis and denutrition].
    Wegmann R; Charbonnier A; Pergola F; Neuman M; Cachin M
    Ann Histochim; 1970; 15(3):157-80. PubMed ID: 5515393
    [No Abstract]   [Full Text] [Related]  

  • 14. [Regenerative tendencies in the alcoholic fatty liver under diet. Change in the dietary fat content].
    Irsigler K; Kryspin-Exner K; Mildschuh W
    Acta Hepatosplenol; 1970; 17(2):103-10. PubMed ID: 5524290
    [No Abstract]   [Full Text] [Related]  

  • 15. [On the behavior of some serum enzymatic activities in subjects with progressive muscular dystrophy treated with nucleotide and nucleoside substances. II. Malate dehydrogenase, glutamic oxalacetic transaminase and glutamic-pyruvic transaminase activity].
    Canani MB; Rea F; Capasso DA
    Boll Soc Ital Biol Sper; 1965 Aug; 41(16):901-4. PubMed ID: 5880029
    [No Abstract]   [Full Text] [Related]  

  • 16. Association of serum gamma-glutamyltransferase and alanine aminotransferase activities with risk of type 2 diabetes mellitus independent of fatty liver.
    Kim CH; Park JY; Lee KU; Kim JH; Kim HK
    Diabetes Metab Res Rev; 2009 Jan; 25(1):64-9. PubMed ID: 19065605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.
    Hong XZ; Li LD; Wu LM
    Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnosis of hepatosis].
    Nöcker J; Hartleb O; Weidemann H
    Dtsch Z Verdau Stoffwechselkr; 1966 Feb; 25(6):349-54. PubMed ID: 5998358
    [No Abstract]   [Full Text] [Related]  

  • 19. An assessment of statin safety by hepatologists.
    Cohen DE; Anania FA; Chalasani N;
    Am J Cardiol; 2006 Apr; 97(8A):77C-81C. PubMed ID: 16581333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Possibilities of the treatment of chronic liver diseases with and without vitamin B 12 -folic acid administration].
    Börner E
    Med Welt; 1972 Aug; 23(31):1077-80. PubMed ID: 4647306
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.